Sirolimus vs paclitaxel-coated balloons in in-stent coronary restenosis: A meta-analysis

Table 1 Study characteristics and patient baseline demographics

Ref.	Study design	Country	Follow up period	Sample size		Age, year; mean ± SD		Male (%)		Diabetes mellitus (%)		Hypertension (%)		Hyperlipidemia (%)		Smoking (%)
				SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB	SCB	PCB
Ali et al[7], 2019	RCT	United States	6 months	25	25	61.6 ± 11.7	58.6 ± 21.5	88	76	72	76	96	92	92	84	16	8
Liu et al[20], 2025	RCT	China	12 months	130	128	63.8 ± 9.3	63.7 ± 8.5	73.1	75.8	33.8	41.4	66.9	70.3	17.7	14.1	NA	NA
Ray et al[19], 2025	Prospective observational study	India	41 months	53	32	67.19 ± 8.21	63.50 ± 8.54	86.8	96.9	73.6	81.3	71.7	84.4	N/A	N/A	N/A	N/A
Scheller et al[8], 2022	RCT	Malaysia, German, Switzerland	12 months	50	51	67 ± 12	63 ± 12	86	76	54	59	98	94	88	84	22	12

SCB: Sirolimus coated balloon; PCB: Paclitaxel coated balloon; N/A: Not applicable.